Antiplatelets Are Enough for Nondisabling Strokes

JAMA Neurol. 2023 Dec 1;80(12):1263-1264. doi: 10.1001/jamaneurol.2023.3994.
No abstract available

Plain language summary

This Viewpoint argues, in keeping with current stroke management guidelines, that patients with mild, nondisabling strokes should not receive thrombolysis, even when presenting within the time window for treatment.

MeSH terms

  • Brain Ischemia* / drug therapy
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Stroke* / drug therapy
  • Thrombolytic Therapy

Substances

  • Fibrinolytic Agents